Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S0106A, Proteomic Signatures Associated With Complete Response (CR) and Complete Continuous Response at One Year (CCR1) Following Cytarabine-Based Induction Chemotherapy in Younger Adult Patients (18-60 Years of Age) With a Newly Diagnosed Non-M3 AML

NCT01360125 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT01360125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01360125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S0106A, Proteomic Signatures Associated With Complete Response (CR) and Complete Continuous Response at One Year (CCR1) Following Cytarabine-Based Induction Chemotherapy in Younger Adult Patients (18-60 Years of Age) With a Newly Diagnosed Non-M3 AML
Lead sponsor
SWOG Cancer Research Network
Phase
Observational
Overall status
Completed
Start date
June 30, 2011
Completion date
December 31, 2015
Enrollment
310 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia